Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 3 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Psychiatric Rehabilitation 3Early Intervention, Educational 3Carboplatin 3Behavior Therapy 3Surgical Procedures, Operative 2Specimen Handling 2Platinum 2Palliative Care 2Methods 2Hyperthermic Intraperitoneal Chemotherapy 2Gene Expression Profiling 2Cisplatin 2Blood Specimen Collection 2taxane 1oregovomab 1motexafin lutetium 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Touch 1Taxes 1Standard of Care 1Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization 1Sodium Chloride 1Serotonin Plasma Membrane Transport Proteins 1Radiotherapy 1Propranolol 1Preoperative Exercise 1Practice Guidelines as Topic 1Polymerase Chain Reaction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Fallopian Tube Neoplasms × oregovomab × Clear all
NCT00551265 2017-07-14

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

GOG Foundation

Phase NA Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡